• Home
  •  / Apollo Endosurgery

Apollo Endosurgery

OverviewSuggest Edit

Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.) Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.
TypePrivate
Founded2006
HQAustin, USMap
Websiteapolloendo.com
Employee Ratings3.2More
View Jobs (6)

Recent NewsAll News

Latest Updates

Employees (est.) (Oct 2019)299
Job Openings6
Revenue (FY, 2018)$60.9 M(-5%)

Key People/Management at Apollo Endosurgery

Todd Newton

Todd Newton

CEO
Stefanie Cavanaugh

Stefanie Cavanaugh

CFO
Christopher J. Gostout

Christopher J. Gostout

Chief Medical Officer
Bret Schwartzhoff

Bret Schwartzhoff

Vice President, US Sales and Global Marketing
Tiffanie Gilbreth

Tiffanie Gilbreth

Vice President, Clinical and Medical Affairs
Mike Gutteridge

Mike Gutteridge

Vice President, International Sales and Marketing
Show more

Apollo Endosurgery Office Locations

Apollo Endosurgery has an office in Austin
Austin, US (HQ)
1120 S Capital of Texas Hwy #300
Show all (1)

Apollo Endosurgery Financials and Metrics

Summary Metrics

Founding Date

2006

Apollo Endosurgery total Funding

$186.8 m

Apollo Endosurgery latest funding size

$22 m

Time since last funding

4 years ago

Apollo Endosurgery investors

UT Horizon Fund, HIG Capital
Apollo Endosurgery's latest funding round in November 2015 was reported to be $22 m. In total, Apollo Endosurgery has raised $186.8 m
Show all financial metrics

Apollo Endosurgery Revenue

Apollo Endosurgery's revenue was reported to be $60.85 m in FY, 2018
USD

Revenue (Q2, 2019)

14.3m

Gross profit (Q2, 2019)

7.2m

Gross profit margin (Q2, 2019), %

50.3%

Net income (Q2, 2019)

(8.8m)

EBIT (Q2, 2019)

(7.2m)

Cash (30-Jun-2019)

22.9m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

8.0m1.6m64.9m64.3m60.9m

Cost of goods sold

25.3m24.6m27.7m

Gross profit

39.6m39.7m33.2m

Gross profit Margin, %

61%62%55%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

2.6m1.7m1.3m1.1m783.9k747.6k61.3k9.6k9.2k23.8k14.6m17.1m16.5m15.7m15.8m14.1m13.2m14.3m

Cost of goods sold

5.1m6.6m6.0m6.6m6.6m6.4m6.0m7.1m

Gross profit

9.5m10.5m10.5m9.2m9.2m7.7m7.2m7.2m

Gross profit Margin, %

65%61%64%58%58%55%55%50%
show all
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

11.9m8.9m19.1m30.5m24.0m

Accounts Receivable

1.3m7.0k10.5m

Inventories

12.2m14.3m9.9m

Current Assets

13.5m9.3m43.6m57.6m48.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

14.9m16.1m14.3m20.5m12.7m11.9m11.6m7.0m4.7m3.3m8.3m34.4m28.4m30.0m22.9m

Accounts Receivable

622.2k2.7m1.3m2.1m1.4m731.9k56.0k9.6k9.2k24.9k

Inventories

11.7m15.0m13.3m10.4m10.6m

Current Assets

15.8m19.3m16.0m24.2m14.5m12.9m11.8m7.3m5.3m4.0m32.1m62.1m53.1m54.3m47.8m
show all
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(6.6m)(10.0m)(41.2m)(27.3m)(45.8m)

Depreciation and Amortization

196.2k467.0k9.1m9.7m9.3m

Inventories

(3.1m)(2.8m)3.0m

Accounts Payable

(179.4k)(3.0m)523.0k4.7m(1.3m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(5.2m)(3.3m)(7.0m)(10.2m)(2.8m)(5.4m)(7.7m)(1.9m)(4.6m)(3.7m)(8.2m)(15.1m)(20.0m)(8.1m)(17.7m)(27.4m)(2.8m)(11.6m)

Depreciation and Amortization

161.5k35.9k98.9k167.0k142.4k262.3k45.4k672.3k2.4m4.9m7.3m2.4m4.7m7.0m1.1m2.2m

Inventories

514.0k653.0k(729.0k)(1.2m)(1.0m)439.0k(502.0k)(659.0k)

Accounts Payable

(271.8k)502.0k195.4k131.6k2.0m(1.5m)(2.0m)(164.7k)(260.3k)894.6k916.0k4.8m3.3m272.0k(3.7m)(3.0m)1.6m1.6m
show all
USDY, 2019

Financial Leverage

4.1 x
Show all financial metrics

Apollo Endosurgery Online and Social Media Presence

Apollo Endosurgery's Trends

Embed Graph

Apollo Endosurgery News and Updates

September 26, 2018

Global Intragastric Balloons Market 2018-2022 - Key Vendors are Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Lifesciences & Spatz FGIA

DUBLIN, Sept. 26, 2018 /PRNewswire/ -- The "Global Intragastric Balloons Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Intragastric Balloons Market to grow at a CAGR of 25.18% during the period 2018-2022. The report has been prepared based on an...
June 26, 2018

Apollo Endosurgery Makes Good Progress

Apollo Endosurgery Blogs

September 18, 2019

Apollo Endosurgery Receives 510(k) Clearance for Polypropylene Suture-Anchor Assembly

Dateline City: AUSTIN, Texas AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has …
August 23, 2019

Apollo Endosurgery, Inc. – Annual Report for the year ended December 31, 2018

File: Form_10K_2018.pdf (658.55 KB) Related Materials See with SEC Filings Language: English
August 12, 2019

Apollo Endosurgery, Inc. Announces Closing of $20 Million Private Placement of Convertible Debentures

Dateline City: AUSTIN, Texas AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has …
August 08, 2019

Apollo Endosurgery, Inc. Announces $20 Million Private Placement of Convertible Debentures

Dateline City: AUSTIN, Texas AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has …
July 26, 2019

10-Q Second Quarter 2019

File: 10Q-2019-Q2-APEN.pdf (474.07 KB) Language: English
July 24, 2019

Conference Call Transcript - Apollo Endosurgery 2Q 2019

File: Apllo_Endosurgery_-_Q2_2019_Transcript.pdf (229.22 KB) Language: English
Show more

 Apollo Endosurgery Frequently Asked Questions

  • When was Apollo Endosurgery founded?

    Apollo Endosurgery was founded in 2006.

  • Who are Apollo Endosurgery key executives?

    Apollo Endosurgery's key executives are Todd Newton, Stefanie Cavanaugh and Christopher J. Gostout.

  • How many employees does Apollo Endosurgery have?

    Apollo Endosurgery has 299 employees.

  • What is Apollo Endosurgery revenue?

    Latest Apollo Endosurgery annual revenue is $60.9 m.

  • What is Apollo Endosurgery revenue per employee?

    Latest Apollo Endosurgery revenue per employee is $203.5 k.

  • Who are Apollo Endosurgery competitors?

    Competitors of Apollo Endosurgery include Optim, Repro Med Systems and Medequip.

  • Where is Apollo Endosurgery headquarters?

    Apollo Endosurgery headquarters is located at 1120 S Capital of Texas Hwy #300, Austin.

  • Where are Apollo Endosurgery offices?

    Apollo Endosurgery has an office in Austin.

  • How many offices does Apollo Endosurgery have?

    Apollo Endosurgery has 1 office.